Pharmaeconomica's Innovative Partnership Opportunities
Step into the world of innovation with Pharmaeconomica. Our current projects are on the cutting edge of pharmaceutical research, and we're inviting you to join us in shaping the future of healthcare through partnerships. From AI-driven drug discovery to groundbreaking diagnostics and therapies, our projects are opportunities for collaboration that can redefine healthcare. Let's accelerate discoveries and improve lives together. Explore our projects and be part of the future of healthcare.
Peptide Engineering: GPR10 Agonists for Obesity
Pharmaeconomica is revolutionizing obesity treatment with a first-in-class GPR10-targeted drug. Despite the challenges of peptide targeting and the absence of a crystal structure, our expertise in GPCR modeling, homology modeling, and peptide-based drug discovery sets us apart. Utilizing advanced in-silico tools and stabilizing peptides to enhance efficacy, we offer a novel mechanism of action, providing a safer alternative to current GLP-1 receptor treatments like Ozempic and Wegovy.
With obesity projected to affect 25% of the global population by 2035 and the treatment market expected to grow from $24 billion in 2023 to $131 billion by 2028, Pharmaeconomica is poised to capture a significant share of this market. Our innovative approach promises substantial physiological benefits with fewer side effects, making us a compelling investment opportunity.
Vaccine Development: Tackling Evolving Pathogens with Precision!
Pharmaeconomica addresses the challenges of developing vaccines for rapidly evolving pathogens through a versatile pipeline that identifies peptide vaccine candidates. By focusing on highly conserved, non-allergenic, and non-toxic B-cell and T-cell epitopes, we induce robust humoral and cellular immune responses essential for comprehensive immunity.
The global vaccine market, valued at $46.88 billion in 2019, is projected to reach $104.87 billion by 2027. Pharmaeconomica's innovative approach leverages advanced computational tools to develop effective vaccines, positioning us to capture a significant share of this expanding market while providing long-lasting, broad-spectrum immunity against evolving threats.
Peptide-Based Lateral Flow Assay (LFA) for Alzheimer's Disease Diagnosis
We propose a collaborative effort to revolutionize Alzheimer's disease (AD) diagnosis, addressing the global challenges of underdetection and delayed intervention. Our innovative approach utilizes blood-based biomarkers (BBB) for enhanced accuracy in early detection, offering a non-invasive and cost-effective solution suitable for large-scale screening.
By broadening diagnostic assays to include diverse biomarkers, we aim to create multiplex Lateral Flow Assays (LFAs) that simultaneously detect various AD-related proteins within a single sample. Leveraging advancements in peptide science, our project seeks to identify scalable peptide ligands with high specificity and affinity for AD biomarkers. This collaborative endeavor aims to improve patient care and management by providing an early, accurate, and accessible method for AD diagnosis. Let's join forces to make a significant impact on Alzheimer's research and healthcare worldwide.
Pioneering AI-Driven Ebola Therapies
Pharmaeconomica has made an interesting discovery in developing therapeutic agents against the Ebola virus (EBOV), identifying several lead compounds with inhibitory activity against the Ebola glycoprotein (GP). Our most potent compound demonstrated an IC50 value of 10.6 µM. By combining computational strategies and biological assays, we utilized structure-based virtual screening (SBVS) to target the GP, crucial for viral entry.
This discovery presents a compelling investment opportunity. The global antiviral market is expanding, driven by the need for effective treatments. Optimizing these lead compounds could position Pharmaeconomica as a leader in Ebola therapeutics. Our advanced computational methods and rigorous validation processes reduce development time and costs, promising substantial returns for investors and significant benefits for global health.
Novel multitargeted compounds against HIV
The global HIV drugs market, valued at USD 34.13 billion in 2023, is projected to reach USD 58.24 billion by 2032, driven by a CAGR of 6.2%. With 39 million people living with HIV by the end of 2022, there is a critical need for effective treatments. Our innovative approach employs virtual screening to target key HIV proteins—protease, integrase, and reverse transcriptase. We screened 1.5 million compounds, identifying stable, strong binders through molecular docking and MD simulations. In vitro testing on TZM-bl cells showed promising results against HIV-1 strains NL4.3 WT and BaL, with compounds demonstrating high effectiveness and minimal cytotoxicity. These findings underscore the potential of our multitargeted compounds for effective antiretroviral therapies. Further optimization and detailed studies are underway to advance these compounds to clinical applications, presenting a significant investment opportunity in the fight against HIV.
